Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial

Also Read

• Rehabilitated Green Sea Turtle ‘Jurassic’ Released Back into Atlantic After Recovery
• Right Livelihood Award Recognizes AI Ethics Pioneer and Women’s Rights Champions
• Parliamentary Committee Mandates Comprehensive Capital Market Overhaul to Strengthen Regulatory Framework and Investor Protection
• Israeli Prime Minister Says Diverted Flydubai Flight Was Not a Kidnapping